BIOMILQ seeks to disrupt the multibillion-dollar infant formula market
BIOMILQ – another startup producing breastmilk by culturing human mammary cells – is targeting the four fifths of women who transition to dairy-based formula before the recommended six-month exclusivity period for breastfeeding, but aren’t always happy about it, says co-founder Dr Leila Strickland.
“Whether it’s low milk production, medical challenges, incompatible workplaces, or the ongoing stigma around breastfeeding in public, mothers often feed infant formula out of necessity rather than preference.
“While there is no replacement for breastmilk, we believe we can harness the power of science, technology, and nature to deliver comprehensive and sustainable infant nutrition."
